Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps1 finding from 1 reviewBiologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 784 participantsHigh
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)Disease severity ‐ VAS (range 0 to 10, lower = better) · patients with severe chronic rhinosinusitis with nasal polyps1 finding from 1 reviewBiologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 784 participantsModerate
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps1 finding from 1 reviewBiologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 784 participantsModerate
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)Extent of disease ‐ CT scan (lower score = better) · patients with severe chronic rhinosinusitis with nasal polyps1 finding from 1 reviewBiologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 784 participantsHigh